Abstract Comprehensive Genomic Profiling (CGP) and Homologous Recombination Deficiency (HRD) testing are critical components of precision oncology, guiding therapeutic decisions across a range of solid tumors. While CGP provides broad mutational insights, HRD status offers predictive value for PARP inhibitor response. However, integrating both assays into a streamlined workflow remains challenging due to reagent compatibility, workflow complexity, and sample limitations. QIAseq xHYB Pro is a next-generation hybrid-capture reagent chemistry designed to accelerate high-sensitivity, low-input genomic analysis for cancer research. Its optimized protocol enables a single-day hybrid capture workflow, with hybridization completed in minutes rather than hours, dramatically reducing turnaround time without compromising data quality. Among its key applications are HRD and CGP, two essential assays for therapeutic stratification and biomarker discovery. The HRD panel, developed in collaboration with Myriad Genetics, enables detection of genomic instability signatures including loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST). Using QIAseq xHYB Pro, HRD can be deployed as a standalone assay (QIAseq xHYB HRD Panel) or integrated as a spike-in module within the QIAseq xHYB CGP Panel. This modularity allows researchers to flexibly configure assays based on study needs, enabling broad and deep tumor characterization from limited FFPE samples in a single, efficient workflow. Citation Format: Peter Hahn, Markus Storbeck, Krishna Amin, Jonathan Shaffer, Leif Schauser. Accelerating integrated tumor profiling with QIAseq xHYB Pro: A fast, modular approach to CGP and HRD assessment abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 473.
Hahn et al. (Fri,) studied this question.